Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Although tissue plasminogen activator (tPA) has been approved for use in acute ischemic stroke, concerns linger regarding its safety. We analyzed whether patients in special subgroups (i.e., age >70 years, baseline National Institute of Health Stroke Scale (NIHSS) score >20, diabetes, congestive heart failure (CHF), and of Hispanic origin) have a higher risk of symptomatic intracerebral hemorrhage (SICH) than patients without these characteristics.
Four prospective observational studies of acute ischemic stroke patients treated within 3 h with Alteplase were identified and individual patient data were pooled for this analysis. These included the Standard Treatment with Alteplase to Reverse Stroke Study [STARS, N = 389], Epidemiology Study of Ischemic Stroke [ESIS, N = 236], University Of Texas Houston Stroke Study [UT, N = 241], and Canadian Activase For Stroke Effectiveness Study [CASES, N = 1100]. The risk of SICH was calculated for all patients and for each of five subgroups.
A total of 1966 patients were studied. Overall the risk of symptomatic ICH was 4.7% (95%CI, 3.8–5.8%) and the risk was similar among patients with and without each of the five characteristics. Patients with advanced age, baseline NIHSS score >20, CHF or diabetes had increased mortality and significantly lower rate of functional recovery.
The present study suggests that these specified subgroups of patients are not at increased risk of SICH after stroke thrombolysis compared to those without these characteristics.
- Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice. A meta-analysis of safety data. Stroke 2003;34:2847–50. CrossRef
- NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–7. CrossRef
- Larrue V, von Kummer R, del Zoppo G, Bluhmki T. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957–60.
- The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109–18.
- Larrue V, von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study. Stroke 2001;32:438–41.
- Hill MD, Buchan AM, for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307–12.
- Okada Y, Yamaguchi T, Minematsu K, Miyashita T, Sawada T, Sadoshima S et␣al. Hemorrhagic transformation in cerebral embolic stroke. Stroke 1989;20:589–603.
- Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M et␣al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator for acute ischemic stroke in clinical practice: the Multicenter rt-PA Acute Stroke Survey. Circulation 2002;105:1679–85. CrossRef
- Gurwitz JH, Gore JM, Gold berg RJ, Barron HV, Breen T, Rundle AC et␣al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: participants in the national registry of myocardial infarction 2. Ann Intern Med 1998;129:597–604.
- Tanne D, Gorman MJ, Bates VE, Kasner SE, Scott P, Verro P et␣al. The tPA Stroke Survey Group. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older. The tPA Stroke Survey experience. Stroke 2000;31:370–5.
- Berrouschot J, Röther J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (≥80 years) stroke patients. Stroke 2005;36:2421–5. CrossRef
- Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis for acute ischemic stroke patients aged 80 years and older: Canadian Alteplase for stroke effectiveness study. J Neurol Neurosurg Psychiatry 2006;77:826–29. CrossRef
- Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J et␣al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831–1838. CrossRef
- Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH et␣al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34–39.
- Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG et␣al. and PROACT II investigators. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke. the PROACT II trial. Neurology 2001;57:1603–10.
- Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA et␣al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151–8. CrossRef
- Stansbury JP, Huanguang J, Williams LS, Vogel WB, Duncan PW. Ethnic disparities in stroke: epidemiology,acute care and postacute outcomes. Stroke 2005;36:374–87. CrossRef
- Frey JL, Jahnke HK, Bulfinch EW. Differences in stroke between white, Hispanic, and Native American patients. the Barrow Neurological Institute stroke database. Stroke 1998;29:29–33.
- Trouillas P, Nighoghossian N, Derex L, Adeleine P, Honnorat J, Neuschwander P et␣al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological,topographic,and radiological outcome factors. Stroke 1998;29:2529–40.
- Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics
Volume 6, Issue 3 , pp 181-185
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Tissue plasminogen activator
- Acute ischemic stroke
- Industry Sectors
- Author Affiliations
- 1. Calgary Stroke Program, Department of Clinical Neurosciences, Foot hills Medical Center, Foot hills Hospital, Room 1242A, University of Calgary, Calgary, AB, Canada, T2N2T9
- 2. Genentech Inc., South San Francisco, CA, USA
- 3. Stroke Program, Department of Neurology, University of Texas Health Sciences Center, Houston, TX, USA
- 4. Stanford University Department of Neurology, Stanford, CA, USA